EVAX

Evaxion Biotech A/S ADR · NASDAQ

Sector Health Technology
Industry Biotechnology
Website evaxion-biotech.com
Employees(FY) 63
ISIN US29970R2040

Performance

-7.19%

1W

+4.88%

1M

-9.58%

3M

-66.92%

6M

-43.56%

YTD

-73.85%

1Y

Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.

Advanced Technical Analysis

Technical Analysis of EVAX 2024-05-03

Overview:

In analyzing the technical indicators for EVAX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

Moving Averages (MA): The 5-day MA has been fluctuating around the closing prices, in...

See more ...

Recent News & Updates

2024-05-06 21:15
Sidoti Events, LLC's Virtual May Micro-Cap Conference(Accesswire)
2024-04-16 20:00
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing with Personalized Cancer Vaccine EVX-01(Globenewswire)
2024-04-02 23:26
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data(Zacks)
2024-04-02 20:57
Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-04-01 19:00
Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection(Globenewswire)
2024-03-26 19:30
Evaxion Announces Business Update and Full Year 2023 Financial Results(Globenewswire)
2024-03-18 19:30
Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology Platform(Globenewswire)
2024-02-28 18:30
Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations(Globenewswire)
2024-02-19 18:30
Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD(Globenewswire)
2024-02-06 19:30
Evaxion Regains Compliance with Nasdaq Minimum Bid Price Requirement(Globenewswire)
2024-02-05 19:30
Evaxion Announces Closing of $15 Million Public Offering(Globenewswire)
2024-01-31 20:20
Evaxion Biotech Announces Pricing of $15 Million Public Offering(Globenewswire)
2024-01-23 19:30
Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets(Globenewswire)
2024-01-22 03:30
Evaxion Announces Completion of ADS Ratio Change(Globenewswire)
2024-01-07 19:30
Evaxion Announces Plan to Implement ADS Ratio Change(Globenewswire)
2023-12-21 03:30
Evaxion Biotech Announces Closing of Private Placement(Globenewswire)
2023-12-19 03:15
Evaxion Announces Business Update and Third Quarter 2023 Financial Results(Globenewswire)
2023-12-18 20:25
Evaxion Biotech Announces Private Placement Financing(Globenewswire)
2023-11-27 19:27
Evaxion to Unveil Potentially Groundbreaking AI-Immunology Precision Cancer Vaccine Concept(Globenewswire)
2023-11-14 19:00
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy(Globenewswire)
2023-11-05 21:12
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak(Globenewswire)
2023-10-30 23:15
Evaxion Announces Encouraging Initial Phase 2 Clinical Data on Its Personalized Cancer Vaccine EVX-01(Globenewswire)
2023-10-25 20:30
New and Exciting Clinical Data on Evaxion's AI-Immunology -Based Personalized Cancer Vaccines to be Presented(Globenewswire)
2023-10-04 20:30
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency(Globenewswire)
2023-09-21 01:23
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab(Yahoo Finance)
2023-09-19 20:26
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea(Yahoo Finance)
2023-09-17 20:23
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company(Yahoo Finance)
2023-09-10 20:17
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development(Yahoo Finance)
2023-08-28 20:30
Evaxion announces Executive Management Changes to strengthen the AI-strategy(Yahoo Finance)
2023-08-22 21:19
Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript(Yahoo Finance)

Page 1 of 4

previousnext